NuProbe

4 articles with NuProbe

• NuProbe Closes $42M Fundraising

  1/11/2021

   NuProbe, a genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, announces the closing of its oversubscribed $42M fundraising. The lead investors for this financing round are BioTrack Capital and Yonghua Capital.

• NuProbe and Weigao Group Form Strategic Collaboration to Develop Liquid Biopsy Panel

  6/22/2020

  NuProbe and Weigao Group announced a strategic collaboration, wherein the two parties will apply NuProbe's proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). The product will be compatible with the desktop NGS instruments, and the companies plan to l

• NuProbe Announced New Clinical Advisory Board Members from Yale and MD Anderson, Launched NGS Multi-gene Panels

  4/22/2020

  NuProbe, a molecular diagnostic startup, announced the addition of two world-renowned oncologists to their clinical advisory board: Amir A. Jazaeri, M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel, M.D., Ph.D., from Yale University School of Medicine.

• NuProbe Forms Scientific Advisory Board and Appoints New Director

  7/24/2018

  ​NuProbe Global announced today the formation of its Scientific Advisory Board (SAB) with genomics pioneers George M. Church, Ph.D. and David R. Walt, Ph.D.